Form 4: Amgen EVP David M. Reese Reports Stock Transaction
SEC Form 4 Filing
David M. Reese, EVP & Chief Technology Officer of Amgen, reports the disposition of 650 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.
Summary
- On May 2, 2024, David M. Reese, EVP & Chief Technology Officer of Amgen Inc., reported a transaction involving Amgen's common stock.
- Reese disposed of 650 shares at a price of $277.37 per share.
- Following the transaction, Reese beneficially owns 59,326 shares of Amgen common stock.
- These shares include Restricted Stock Units (RSUs) that will vest on various dates in the future, as well as Dividend Equivalents (DEs).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, and the transaction is a routine part of executive compensation. Therefore, the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Amgen.
Stakeholder Impact
- The transaction has a minimal impact on shareholders, as it is a small percentage of the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/02/2024 | Date of stock transaction and filing of Form 4. |
| 05/05/2024 | 1,180 RSUs will vest. |
| 04/30/2025 | 1,363 RSUs will vest. |
| 05/02/2025 | 1,286 RSUs will vest. |
| 05/02/2026 | 1,325 RSUs will vest. |
| 05/02/2025 | 1,258 RSUs will vest. |
| 05/02/2026 | 1,259 RSUs will vest. |
| 05/02/2027 | 1,297 RSUs will vest. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.